Efficacy of avatrombopag in patients with immune thrombocytopenia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Thrombopoietin receptor agonists are considered second-line therapy and are prescribed to patients with insufficient response or intolerance to first-line therapy. These drugs, which stimulate platelet production by activating the thrombopoietin receptor, are effective and safe for both short-term and long-term treatment of immune thrombocytopenia. They provide high response rates in 70–80 % of patients and sustained remission in 10–30 %. The response to long-term use of thrombopoietin receptor agonists lasts for 6–8 years or more and allows for the reduction or discontinuation of corticosteroid and immunosuppressant use, as well as a halving of the incidence of bleeding.

Aim. To evaluate the efficacy of the thrombopoietin receptor agonist avatrombopag in patients with immune thrombocytopenia.

Materials and methods. The study included 45 patients with immune thrombocytopenia who received avatrombopag orally once daily, starting with a dose of 20 mg and subsequently titrated to achieve and maintain a platelet count of at least 50 × 109 / L. Statistical data were processed using GraphPad Prism 9, and differences between pre- and post-therapy were assessed using the Wilcoxon signed-rank test (p < 0.05).

Results. The results of the study demonstrate a statistically significant increase in platelet counts among patients with immune thrombocytopenia treated with avatrombopag.

Conclusion. The use of avatrombopag appears justified as a second-line treatment for immune thrombocytopenia.

About the authors

Sergey G. Zakharov

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Author for correspondence.
Email: hematologymoniki@mail.ru
ORCID iD: 0000-0003-2847-4374
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110

T. A. Mitina

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: hematologymoniki@mail.ru
ORCID iD: 0000-0001-7493-0030
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110

A. V. Zakharova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: hematologymoniki@mail.ru
ORCID iD: 0009-0008-0134-1049
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110

N. A. Demakova

Belgorod National Research University

Email: hematologymoniki@mail.ru
Russian Federation, 85 Pobedy St., Belgorod 308015

Yu. B. Chernykh

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: hematologymoniki@mail.ru
ORCID iD: 0000-0002-7271-1560
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110

K. A. Belousov

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: hematologymoniki@mail.ru
ORCID iD: 0000-0001-9028-7671
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110

L. L. Vysotskaya

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: hematologymoniki@mail.ru
ORCID iD: 0000-0002-4604-2842
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110

E. V. Trifonova

M.F. Vladimirskiy Moscow Regional Research Clinical Institute

Email: hematologymoniki@mail.ru
ORCID iD: 0000-0002-1576-1449
Russian Federation, 61 / 2 Shchepkina St., Moscow 129110

References

  1. Melikyan A.L., Pustovaya E.I., Tsvetaeva N.V. et al. Guidelines for the diagnosis and management of idiopathic thrombocytopenic purpura. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2023;68(4):530–55. (In Russ.). doi: 10.35754/0234-5730-2022-68-4-530-555
  2. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from international working group. Blood 2009;113(11):2386–93. doi: 10.1182/blood-2008-07-162503
  3. Lambert M.P., Gernsheimer T.B. Clinical updates in adult immune thrombocytopenia. Blood 2017;129(21):2829–35. doi: 10.1182/blood-2017-03-754119
  4. Długosz-Danecka M., Zdziarska J., Jurczak W. Avatrombopag for the treatment of immune thrombocytopenia. Expert Rev Clin Immunol 2019;15(4):327–39. doi: 10.1080/1744666X.2019.1587294
  5. Melikyan A.L., Pustovaya E.I., Kalinina M.V. et al. Epidemiological characteristics of primary immune thrombocytopenia in adult population of the Russian Federation. Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinickeskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2017;4(10):558–9. (In Russ.).
  6. Provan D., Stasi R., Newland A.S. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–86. doi: 10.1182/blood-2009-06-225565
  7. Doobaree I.U., Nandigram R., Bennett D. et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Hematol 2016;97(4): 321–30. doi: 10.1111/ejh.12777
  8. Zakharov S.G., Mitina T.A., Zakharova A.V. et al. Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia. Onkogematologiya = Oncohematology 2024;19(2):109–17. (In Russ.). doi: 10.17650/1818-8346-2024-19-2-109-117
  9. Cines D.B., Cuker A., Semple J.W. Pathogenesis of immune thrombocytopenia. Presse Med 2014;43(4 Pt 2):e49–59. doi: 10.1016/j.lpm.2014.01.010
  10. Birocchi S., Podda G.M., Manzoni M. et al. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a metaanalysis and systematic review. Platelets 2021;32(2):216–26. doi: 10.1080/09537104.2020.1745168
  11. Kuter D.J. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev 2022;53:100909. doi: 10.1016/j.blre.2021.100909
  12. Kuter D.J, Bussel J.B., Lyons R.M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371(9610):395–403. doi: 10.1016/S0140-6736(08)60203-2
  13. Kuter D.J., Rummel M., Boccia R. et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363(20):1889–99. doi: 10.1056/NEJMoa1002625
  14. Wong R.S.M., Saleh M.N., Khelif A. et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017;130(23):2527–36. doi: 10.1182/blood-2017-04-748707
  15. Jurczak W., Chojnowski K., Mayer J. et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol 2018;183(3):479–90. doi: 10.1111/bjh.15573
  16. Al-Samkari H., Nagalla S. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets 2022;33(2):257–64. doi: 10.1080/09537104.2021.1881952
  17. Instructions for medical use of the Troplastim. ЛП-№(007349)-(РГ-RU)-231024 (In Russ.).
  18. Cheloff A.Z., AlSamkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med 2019;10:313–21. doi: 10.2147/JBM.S191790
  19. Experts Council Resolution on topical issues in the treatment of patients with idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) and thrombopoietin receptor agonist (avatrombopag). Onkogematologiya = Oncohematology 2022;17(2):151–3. (In Russ.). doi: 10.17650/1818-8346-2022-17-2-151-153
  20. Nagalla S., Tian W., Vredenburg M., Allen L.F. Platelet response to avatrombopag in patients with chronic immune thrombocytopenia: additional analyses from a phase 3 study and its extension. Blood 2019;134(Suppl_1):1071. doi: 10.1182/blood-2019-130963
  21. Instructions for medical use of the Eltrombopag. ЛСР-010032/09 (In Russ.).
  22. Tarantino M.D., Mosalpuria K., Kolodny S. et al. Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA. Blood Adv 2025;9(11):2733–43. doi: 10.1182/bloodadvances.2024015635
  23. Tarantino M.D., Bussel J.B., Lee E.J., Jamieson B.D. A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP. Br J Haematol 2023;202(4):897–9. doi: 10.1111/bjh.18908
  24. Al Samkari H., Jiang D., Gernsheimer T. et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol 2022;197(3):359–66. doi: 10.1111/bjh.18081

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.